In T1DM-complicated pregnancy, CSII compared to MDI therapy resulted in better first trimester glycaemic control; this difference decreased in subsequent trimesters. CSII therapy was associated with lower insulin requirements, higher GWG, and altered risk for infants being LGA and SGA(Clinical and Translational Endocrinology)
Diabetes News
Tag: CSII
Continuous subcutaneous insulin infusion (CSII) therapy at Derby Teaching Hospitals: sustained benefits in glucose control
CSII therapy led to a sustained long-term improvement in glycaemic control in addition to a reduction in self-reported hypoglycaemia (Diabetic Medicine)
A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes
Regardless of which formulas are used, it is important to emphasize that recommended insulin-dosing formulas are intended as estimates, and should always be tempered with clinical judgment, based upon experience, according to patient-specific factors including diurnal variation in blood glucose and activity level (Current Diabetes Reports)
Insulin pump use compared with intravenous insulin during labour and delivery: the INSPIRED observational cohort study
This study demonstrates that the continuation of CSII therapy during labour and delivery appears safe and efficacious. Moreover, women who choose to continue CSII have better glucose control during delivery than those who switch to IV insulin, suggesting that it should be standard practice to allow women the option of continuing CSII during labour and delivery (Diabetic Medicine)
Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study
Treatment with CSII over 4 years independently reduced HbA1c and UACR compared with MDI. Reduced UACR may be due to less glycaemic variability because the effect of CSII on HbA1c could only partially explain the effect (Diabetic Medicine)
Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics
This comprehensive review, which focuses on the European situation, summarises evidence for the efficacy and safety of CSII, particularly when used with RAIAs, in adult, paediatric, and pregnant populations, discusses relevant European guidelines, reviews issues that surround use of this technology, and discusses recent advances in pump technology, including the development of closed-loop ‘artificial pancreas’ systems (Diabetes/Metabolism Research and Reviews)
Glycosmedia is also available as an App: